| Name | Title | Contact Details |
|---|
Renalytix AI plc (LSE AIM: RENX) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease.
MD Communications Group is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Semafore Pharmaceuticals is a Westfield, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ecopia BioSciences Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.